CStone Pharmaceuticals Achieves Primary Endpoint in GEMSTONE-304 Study for Sugemalimab
China-based CStone Pharmaceuticals (HKG: 2616) has announced the achievement of the primary endpoint in the...
3D Medicines Gains FDA Approval for Phase II Study of Envafolimab in dMMR Tumors
China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving approval from the US FDA...
Changzhou Qianhong Completes Phase I Study of QHRD107 for Acute Myeloid Leukemia
China-based Changzhou Qianhong Bio-pharma Co., Ltd (SHE: 002550) has announced the completion of enrollment and...
Guangdong Zhongsheng Completes Enrollment for RAY1216 Phase III Study in COVID-19
China – based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the completion of...
CDE Releases 65th Batch of Chemical Generic Reference Preparations
The Center for Drug Evaluation (CDE) has released the 65th batch of chemical generic reference...
Viking Therapeutics Sues Ascletis Pharma Over Alleged Trade Secret Theft
US – based Viking Therapeutics (NASDAQ: VKTX) is set to take China’s Ascletis Pharma Inc....
Shuwen Biotech Partners with Nottingham University Hospitals for MammaTyper
China – based diagnostic specialist Shuwen Biotech Co., Ltd and its German wholly – owned...
Chinagene Tech’s ZVS101e Receives FDA IND Approval for Bietti’s Crystalline Dystrophy
Beijing – based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has...
Jiangxi Leads 16-Province VBP Alliance with Winning Bids Announced
The Jiangxi Province Healthcare Security Administration has released a notification regarding the winning bids of...
NMPA Approves 172 Medical Devices for Marketing in November 2022
The National Medical Products Administration (NMPA) approved 172 medical devices for marketing in November 2022....
Merck’s Lagevrio Receives Emergency Conditional Approval from China’s NMPA
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced receiving emergency conditional approval...
NHSA and CNIPA Issue Opinions on Strengthening IP Protection in Drug Procurement
The National Healthcare Security Administration (NHSA) and the China National Intellectual Property Administration (CNIPA) have...
Legend Biotech’s Carvykti Accepted for Review by China’s CDE
The Center for Drug Evaluation (CDE) website indicates that a market approval filing from Legend...
F-star Therapeutics and Sino Biopharmaceutical Face Delays in Proposed Acquisition
UK-based biotech F-star Therapeutics (NASDAQ: FSTX) released an SEC filing indicating that the proposed acquisition...
CSPC’s ALMB-0168 Receives NMPA Approval for Osteoarthritis Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...
RemeGen’s RC108 Receives FDA Go-Ahead for Phase I Clinical Study
China-based biopharma RemeGen Ltd (HKG: 9995) has announced receiving approval from the US FDA to...
Simcere Receives NMPA Clearance for SIM0348 Clinical Study
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced receiving clearance from the National Medical Products...
Skynor Medical Raises RMB 100 Million in Financing Round for Market Expansion
Skynor Medical, a Shanghai-based manufacturer of nerve and peripheral blood vessel implantation and interventional devices,...
Sichuan Kelun Completes RMB 1.5 Billion Financing Round for Kelun-Biotech
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced the completion of a financing...
Everest Medicines’ Nefecon Receives Priority Review Recommendation from CDE
China-based Everest Medicines (HKG: 1952) has announced that the Center for Drug Evaluation (CDE) of...